Phase II

The company and the agency discussed the development of SYN-004 (ribaxamase) to prevent antibiotic-mediated Clostridium difficile infection (CDI).

AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days

Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.

Trial Results Anticipated First Half 2019

iX Biopharma Ltd will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark.

Top-line Data Expected Early in the First Quarter of 2019

Galapagos NV reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).

Karolinska Development announces today top line results from a Phase 2b study with tafoxiparin in treatment of protracted labor. The results show that the study did not achieve its primary endpoint of reducing the time to vaginal delivery through treatment with tafoxiparin. Karolinska Development will revalue the portfolio company’s book value, which is expected to negatively impact the result by SEK 40 million for the fourth quarter of 2018.

Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.

VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.